Blueprint Medicines Corp [BPMC] stock is trading at $90.70, up 3.65%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The BPMC shares have gain 9.98% over the last week, with a monthly amount glided 2.99%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Blueprint Medicines Corp [NASDAQ: BPMC] stock has seen the most recent analyst activity on October 24, 2024, when UBS initiated its Neutral rating and assigned the stock a price target of $88. Previously, Stephens started tracking the stock with Overweight rating on May 14, 2024, and set its price target to $140. On May 06, 2024, upgrade upgraded it’s rating to Market Perform and revised its price target to $97 on the stock. Oppenheimer upgraded its rating to a Outperform but stick to its price target of $85 on October 27, 2023. Needham reiterated its recommendation of a Buy and raised its price target to $66 on August 21, 2023. Wells Fargo upgraded its rating to Overweight for this stock on July 31, 2023, and upped its price target to $82. In a note dated June 05, 2023, SVB Securities downgraded an Underperform rating on this stock and revised its target price from $48 to $43.
Blueprint Medicines Corp [BPMC] stock has fluctuated between $56.74 and $121.90 over the past year. Currently, Wall Street analysts expect the stock to reach $109.71 within the next 12 months. Blueprint Medicines Corp [NASDAQ: BPMC] shares were valued at $90.70 at the most recent close of the market. An investor can expect a potential return of 20.96% based on the average BPMC price forecast.
Analyzing the BPMC fundamentals
Blueprint Medicines Corp [NASDAQ:BPMC] reported sales of 434.41M for the trailing twelve months, which represents a growth of 126.61%. Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -0.64%, Pretax Profit Margin comes in at -0.29%, and Net Profit Margin reading is -0.29%. To continue investigating profitability, this company’s Return on Assets is posted at -0.11, Equity is -0.48 and Total Capital is -0.29. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.23.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 88.37 points at the first support level, and at 86.04 for the second support level. However, for the 1st resistance point, the stock is sitting at 91.94, and for the 2nd resistance point, it is at 93.18.
Ratios To Look Out For
For context, Blueprint Medicines Corp’s Current Ratio is 3.32. Also, the Quick Ratio is 3.27, while the Cash Ratio stands at 0.35. Considering the valuation of this stock, the price to sales ratio is 13.75, the price to book ratio is 18.38.
Transactions by insiders
Recent insider trading involved Namouni Fouad, PRESIDENT, R & D, that happened on Oct 03 ’24 when 3633.0 shares were sold. Director, Albers Jeffrey W. completed a deal on Sep 09 ’24 to sell 19702.0 shares. Meanwhile, Director Albers Jeffrey W. bought 19702.0 shares on Sep 09 ’24.
